Rasmuson T, Björk G R
Department of Oncology, University of Umeå, Sweden.
Acta Oncol. 1995;34(1):61-7. doi: 10.3109/02841869509093640.
Urinary excretion of pseudouridine, a modified nucleoside, was assessed in 30 patients with Hodgkin's disease, and 106 patients with non-Hodgkin's lymphoma, classified according to the Kiel system. Elevated excretion was found in 47% of 49 patients with high-grade malignant (HGM) lymphoma, and in 37% of 57 with low-grade malignant (LGM) lymphoma, in 13% in Hodgkin's disease, and 3% in 79 reference individuals. The level of pseudouridine excretion correlated with clinical stage in HGM lymphoma (p < 0.0001), but not in LGM lymphoma or Hodgkin's disease (p = 0.086 and 0.36 respectively). Of 28 patients with B-symptoms 71% had elevated excretion, compared to 26% of 108 without B-symptoms (p < 0.0001). Elevated excretion of pseudouridine before therapy was associated with shorter survival time in LGM lymphoma stage II to IV disease, (p = 0.022), and a similar tendency was also observed in HGM lymphoma. Using Cox proportional hazard model, age, malignancy grade, excretion of pseudouridine, and disease stage were identified as independent prognostic factors in non-Hodgkin's lymphoma.
对30例霍奇金病患者和106例根据基尔系统分类的非霍奇金淋巴瘤患者的假尿苷（一种修饰核苷）尿排泄情况进行了评估。在49例高级别恶性（HGM）淋巴瘤患者中有47%排泄量升高，57例低级别恶性（LGM）淋巴瘤患者中有37%排泄量升高，霍奇金病患者中有13%排泄量升高，79名对照个体中有3%排泄量升高。假尿苷排泄水平与HGM淋巴瘤的临床分期相关（p<0.0001），但与LGM淋巴瘤或霍奇金病无关（分别为p = 0.086和0.36）。在28例有B症状的患者中，71%排泄量升高，而在108例无B症状的患者中这一比例为26%（p<0.0001）。在LGM淋巴瘤II至IV期疾病中，治疗前假尿苷排泄量升高与较短的生存时间相关（p = 0.022），在HGM淋巴瘤中也观察到类似趋势。使用Cox比例风险模型，年龄、恶性程度、假尿苷排泄量和疾病分期被确定为非霍奇金淋巴瘤的独立预后因素。
